This section lists the publications on research conducted as part of the NCER-PD, such as the Luxembourg Parkinson's Study. You can explore the list below, sorted by year, and for some publications, we have alredy made available a summary in English, German and French.
2020
Antony, P.M.A., Kondratyeva, O., Mommaerts, K. et al. (2020) Fibroblast mitochondria in idiopathic Parkinson’s disease display morphological changes and enhanced resistance to depolarization. Sci Rep, 10, 1569. https://doi.org/10.1038/s41598-020-58505-6
Baldini, F., Hertel, J., Sandt, E., Thinnes, C. C., Neuberger-Castillo, L., Pavelka, L., Betsou, F., Krüger, R., & Thiele, I. (2020). Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions. BMC Biology, 18(1), 62. https://doi.org/10.1186/s12915-020-00775-7 >> Read the summary
Barbe, M. T., Tonder, L., Krack, P., Debû, B., Schüpbach, M., Paschen, S., Dembek, T. A., Kühn, A. A., Fraix, V., Brefel-Courbon, C., Wojtecki, L., Maltête, D., Damier, P., Sixel-Döring, F., Weiss, D., Pinsker, M., Witjas, T., Thobois, S., Schade-Brittinger, C., Rau, J., … EARLYSTIM study group (2020). Deep Brain Stimulation for Freezing of Gait in Parkinson's Disease With Early Motor Complications. Movement disorders : official journal of the Movement Disorder Society, 35(1), pp 82–90. https://doi.org/10.1002/mds.27892
Berenguer-Escuder, C., Grossmann, D., Antony, P., Arena, G., Wasner, K., Massart, F., Jarazo, J., Walter, J., Schwamborn, J. C., Grünewald, A., & Krüger, R. (2020). Impaired mitochondrial-endoplasmic reticulum interaction and mitophagy in Miro1-mutant neurons in Parkinson's disease. Human molecular genetics, 29(8), 1353–1364. https://doi.org/10.1093/hmg/ddaa066
Bobbili, D.R., Banda, P., Krüger, R., May, P. (2020) Excess of singleton loss-of-function variants in Parkinson's disease contributes to genetic risk. Journal of Medical Genetics, 57(9), pp 617-623. https://doi.org/10.1136/jmedgenet-2019-106316.
Boussaad, I., Obermaier, C. D., Hanss, Z., Bobbili, D. R., Bolognin, S., Glaab, E., Wołyńska, K., Weisschuh, N., De Conti, L., May, C., Giesert, F., Grossmann, D., Lambert, A., Kirchen, S., Biryukov, M., Burbulla, L. F., Massart, F., Bohler, J., Cruciani, G., Schmid, B., … Krüger, R. (2020). A patient-based model of RNA mis-splicing uncovers treatment targets in Parkinson's disease. Science translational medicine, 12(560), eaau3960. https://doi.org/10.1126/scitranslmed.aau3960 >> Read the summary
Hanss, Z., Boussaad, I., Jarazo, J., Schwamborn, J. C., & Krüger, R. (2020). Quality Control Strategy for CRISPR-Cas9-Based Gene Editing Complicated by a Pseudogene. Frontiers in genetics, 10, 1297. https://doi.org/10.3389/fgene.2019.01297
Larsen, S.B., Hanss, Z., Cruciani, G., Massart, F., Barbuti, P.A., Mellick, G., Krüger, R. (2020) Induced pluripotent stem cell line (LCSBi001-A) derived from a patient with Parkinson's disease carrying the p.D620N mutation in VPS35. Stem Cell Res, 45, 101776. https://doi.org/10.1016/j.scr.2020.101776.
Monzel, A. S., Hemmer, K., Kaoma, T., Smits, L. M., Bolognin, S., Lucarelli, P., Rosety, I., Zagare, A., Antony, P., Nickels, S. L., Krueger, R., Azuaje, F., & Schwamborn, J. C. (2020). Machine learning-assisted neurotoxicity prediction in human midbrain organoids. Parkinsonism & related disorders, 75, 105–109. https://doi.org/10.1016/j.parkreldis.2020.05.011
Ohnmacht, J., May, P., Sinkkonen, L., & Krüger, R. (2020). Missing heritability in Parkinson's disease: the emerging role of non-coding genetic variation. Journal of neural transmission (Vienna, Austria : 1996), 127(5), 729–748. https://doi.org/10.1007/s00702-020-02184-0
Stute, L., & Krüger, R. (2020). [Emerging concepts for precision medicine in Parkinson's disease with focus on genetics]. Fortschritte Der Neurologie-Psychiatrie. https://doi.org/10.1055/a-1149-2204.
Woitalla D, Krüger R, Lorenzl S, et al. (2020) [The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease]. Fortschritte der Neurologie-psychiatrie. https://doi.org/10.1055/a-1149-9308
2019
Bolognin, S., Fossépré, M., Qing, X., Jarazo, J., Ščančar, J., Moreno, E. L., Nickels, S. L., Wasner, K., Ouzren, N., Walter, J., Grünewald, A., Glaab, E., Salamanca, L., Fleming, R., Antony, P., & Schwamborn, J. C. (2018). 3D Cultures of Parkinson's Disease-Specific Dopaminergic Neurons for High Content Phenotyping and Drug Testing. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 6(1), 1800927. https://doi.org/10.1002/advs.201800927
Glaab, E., Trezzi, J. P., Greuel, A., Jäger, C., Hodak, Z., Drzezga, A., Timmermann, L., Tittgemeyer, M., Diederich, N. J., & Eggers, C. (2019). Integrative analysis of blood metabolomics and PET brain neuroimaging data for Parkinson's disease. Neurobiology of disease, 124, 555–562. https://doi.org/10.1016/j.nbd.2019.01.003
Hertel, J., Harms, A. C., Heinken, A., Baldini, F., Thinnes, C. C., Glaab, E., Vasco, D. A., Pietzner, M., Stewart, I. D., Wareham, N. J., Langenberg, C., Trenkwalder, C., Krüger, R., Hankemeier, T., Fleming, R., Mollenhauer, B., & Thiele, I. (2019). Integrated Analyses of Microbiome and Longitudinal Metabolome Data Reveal Microbial-Host Interactions on Sulfur Metabolism in Parkinson's Disease. Cell reports, 29(7), 1767–1777.e8. https://doi.org/10.1016/j.celrep.2019.10.035
Kishore, A., Ashok Kumar Sreelatha, A., Sturm, M., von-Zweydorf, F., Pihlstrøm, L., Raimondi, F., Russell, R., Lichtner, P., Banerjee, M., Krishnan, S., Rajan, R., Puthenveedu, D. K., Chung, S. J., International Parkinson's Disease Genomics Consortium (IPDGC), Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease (COURAGE-PD), Bauer, P., Riess, O., Gloeckner, C. J., Kruger, R., Gasser, T., … Sharma, M. (2019). Understanding the role of genetic variability in LRRK2 in Indian population. Movement disorders : official journal of the Movement Disorder Society, 34(4), 496–505. https://doi.org/10.1002/mds.27558
Nickels, S.L., Walter, J., Bolognin, S., et al. (2019) Impaired serine metabolism complements LRRK2-G2019S pathogenicity in PD patients. Parkinsonism Relat. Disord., 67, pp.48–55.
Riederer, P., Berg, D., Casadei, N., Cheng, F., Classen, J., Dresel, C., Jost, W., Krüger, R., Müller, T., Reichmann, H., Rieß, O., Storch, A., Strobel, S., van Eimeren, T., Völker, H. U., Winkler, J., Winklhofer, K. F., Wüllner, U., Zunke, F., & Monoranu, C. M. (2019). α-Synuclein in Parkinson's disease: causal or bystander?. Journal of neural transmission (Vienna, Austria : 1996), 126(7), 815–840. https://doi.org/10.1007/s00702-019-02025-9
Schuepbach, W., Tonder, L., Schnitzler, A., Krack, P., Rau, J., Hartmann, A., Hälbig, T. D., Pineau, F., Falk, A., Paschen, L., Paschen, S., Volkmann, J., Dafsari, H. S., Barbe, M. T., Fink, G. R., Kühn, A., Kupsch, A., Schneider, G. H., Seigneuret, E., Fraix, V., … EARLYSTIM study group (2019). Quality of life predicts outcome of deep brain stimulation in early Parkinson disease. Neurology, 92(10), e1109–e1120. https://doi.org/10.1212/WNL.0000000000007037
Simons, J. A., Vaillant, M., Hipp, G., Pavelka, L., Stute, L., Pauly, C., & Krüger, R. (2019). Multilingual Validation of the First French Version of Munich Dysphagia Test-Parkinson's Disease (MDT-PD) in the Luxembourg Parkinson's Study. Frontiers in neurology, 10, 1180. https://doi.org/10.3389/fneur.2019.01180
Vollstedt, E. J., Kasten, M., Klein, C., & MJFF Global Genetic Parkinson's Disease Study Group (2019). Using global team science to identify genetic parkinson's disease worldwide. Annals of neurology, 86(2), 153–157. https://doi.org/10.1002/ana.25514
2018
Blauwendraat, C., Reed, X., Kia, D. A., Gan-Or, Z., Lesage, S., Pihlstrøm, L., Guerreiro, R., Gibbs, J. R., Sabir, M., Ahmed, S., Ding, J., Alcalay, R. N., Hassin-Baer, S., Pittman, A. M., Brooks, J., Edsall, C., Hernandez, D. G., Chung, S. J., Goldwurm, S., Toft, M., … COURAGE-PD (Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson’s Disease) Consortium, the French Parkinson’s Disease Consortium, and the International Parkinson’s Disease Genomics Consortium (IPDGC) (2018). Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease. JAMA neurology, 75(11), 1416–1422. https://doi.org/10.1001/jamaneurol.2018.1885
Fitzgerald, J.C., Zimprich, A., Reddy Bobbili, D., Sharma, M., May, P., Krüger, R. (2018) Reply: No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson's disease. Brain, 141(3), p. e17, https://doi.org/10.1093/brain/awx380
Hipp, G., Vaillant, M., Diederich, N. J., Roomp, K., Satagopam, V. P., Banda, P., Sandt, E., Mommaerts, K., Schmitz, S. K., Longhino, L., Schweicher, A., Hanff, A. M., Nicolai, B., Kolber, P., Reiter, D., Pavelka, L., Binck, S., Pauly, C., Geffers, L., Betsou, F., … Krüger, R. (2018). The Luxembourg Parkinson's Study: A Comprehensive Approach for Stratification and Early Diagnosis. Frontiers in aging neuroscience, 10, p 326. https://doi.org/10.3389/fnagi.2018.00326
Klucken, J., Krüger, R., Schmidt, P., & Bloem, B. R. (2018). Management of Parkinson's Disease 20 Years from Now: Towards Digital Health Pathways. Journal of Parkinson's disease, 8(s1), S85–S94. https://doi.org/10.3233/JPD-181519
Larsen, S. B., Hanss, Z., & Krüger, R. (2018). The genetic architecture of mitochondrial dysfunction in Parkinson's disease. Cell and tissue research, 373(1), 21–37. https://doi.org/10.1007/s00441-017-2768-8
Lhommee, E., Wojtecki, L., Czernecki, V., Witt, K., Maier, F., Tonder, L., Timmermann, L., Halbig, T. D., Pineau, F., Durif, F., Witjas, T., Pinsker, M., Mehdorn, M., Sixel-Doring, F., Kupsch, A., Krüger, R., Elben, S., Chabardes, S., Thobois, S., Brefel-Courbon, C., Ory-Magne, F., Regis, J.-M., Maltete, D., Sauvaget, A., Rau, J., Schnitzler, A., Schupbach, M., Schade-Brittinger, C., Deuschl, G., Houeto, J.-L., & Krack, P. (2018). Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurol., 17(3), pp. 223-231. doi: 10.1016/S1474-4422(18)30035-8.
Riederer, P., Jellinger, K. A., Kolber, P., Hipp, G., Sian-Hülsmann, J., & Krüger, R. (2018). Lateralisation in Parkinson disease. Cell and tissue research, 373(1), 297–312. https://doi.org/10.1007/s00441-018-2832-z
2017
Antonini, A., Poewe, W., Chaudhuri, K. R., Jech, R., Pickut, B., Pirtošek, Z., Szasz, J., Valldeoriola, F., Winkler, C., Bergmann, L., Yegin, A., Onuk, K., Barch, D., Odin, P., Amalia, E., Arnold, G., Bajenaru, O., Bergmans, B., Bjornara, K. A., ... GLORIA study co-investigators (2017). Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism and Related Disorders, 45, pp 13-20. https://doi.org/10.1016/j.parkreldis.2017.09.018
Ashrafi, A., Garcia, P., Kollmus, H., Schughart, K., del Sol, A., Buttini, M., Glaab, E. (2017) Absence of regulator of G-protein signaling 4 does not protect against dopamine neuron dysfunction and injury in the mouse 6-hydroxydopamine lesion model of Parkinson's disease, Neurobiology of Aging, 58, pp. 30, doi: 10.1016/j.neurobiolaging.2017.06.008
Blauwendraat, C., Faghri, F., Pihlstrom, L., Geiger, J. T., Elbaz, A., Lesage, S., May, P., Aude, N., Abramzon, Y., Murphy, N. A., Gibbs, J. R., Ryten, M., Ferrari, R., Bras, J., Guerreiro, R., Williams, J., Sims, R., Lubbe, S., Hernandez, D. G., Mok, K. Y., Robak, L., Camphell, R. H., Rogaeva, E., Traynor, B. J., Chia, R., Chung, S. J., International Parkinson’s Disease Genomics Consortium (IPDGC), COURAGE-PD Consortium, Glaab, E., Balling, R., Hardy, J. A., Brice, A., Houlden, H., Shulman, J. M., Morris, H. R., Gasser, T., Heutink, P., Krüger, R., Sharma, M., Simon-Sanchez, J., Nalls, M. A., Singleton, A. B., & Scholz, S. W. (2017) NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiology of Aging, 57, pp 247.e9-247.e13. https://doi.org/10.1016/j.neurobiolaging.2017.05.009
Bobbili, D. R., May, P., & Krüger, R. (2017). Rare variant analysis of the PPMI dataset to uncover the complex genetic architecture of Parkinson’s disease. Movement Disorders : Official Journal of the Movement Disorder Society, 322(Supplement S2), 405.
Burbulla, L. F., Song, P., Mazzulli, J. R., Zampese, E., Wong, Y. C., Jeon, S., Santos, D. P., Blanz, J., Obermaier, C. D., Strojny, C., Savas, J. N., Kiskinis, E., Zhuang, X., Krüger, R., Surmeier, D. J., & Krainc, D. (2017). Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease. Science, 357(6357), 1255-1261. https://doi.org/10.1126/science.aam9080 >> Read the summary
Fitzgerald, J. C., Zimprich, A., Carvajal-Berrio, D. A., Schindler, K. M., Maurer, B., Schulte, C., Bus, C., Hauser, A.-K., Kübler, M., Lewin, R., Bobbili, D. R., Schwarz, L. M., Vartholomaiou, E., Brockmann, K., Wüst, R., Madlung, J., Nordheim, A., Riess, O., Martins, L. M., Glaab, E., May, P., Schenke-Layland, K., Picard, D., Sharma, M., Gasser, T., & Krüger, R. (2017). Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson's disease. Brain : A Journal of Neurology, 140(9), 2444-2459.
Glaab, E. (2017) Computational systems biology approaches for Parkinson's disease, Cell and Tissue Research (Special issue Parkinson's disease: Molecules, cells, and circuitries, T. Gasser, H. Braak, K. Del Tredici, Eds.), pp. 1, doi: 10.1007/s00441-017-2734-5
Kolber, P., Stallinger, C., & Krüger, R., (2017). Update zur intensivierten Therapie des fortgeschrittenen idiopathischen Parkinson-Syndroms, Nervenheilkunde, 36(8), pp. 647–654.
Krüger, R., Lingor, P., Doskas, T., Henselmans, J., Danielsen, E. H., de Fabregues, O., Stefani, A., Sensken, S. C., Parra, J. C., Onuk, K., Yegin, A., & Antonini, A. (2017). An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients. Advances in therapy, 34(7), 1741–1752. https://doi.org/10.1007/s12325-017-0571-2
Krüger, R., Klucken, J., Weiss, D., Tönges, L., Kolber, P., Unterecker, S., Lorrain, M., Baas, H., Müller, T., & Riederer, P. (2017). Classification of advanced stages of Parkinson's disease: translation into stratified treatments. Journal of neural transmission (Vienna, Austria : 1996), 124(8), 1015–1027. https://doi.org/10.1007/s00702-017-1707-x >> Read the summary
Scholten, M., Klemt, J., Heilbronn, M., Plewnia, C., Bloem, B. R., Bunjes, F., Krüger, R., Gharabaghi, A., & Weiss, D. (2017). Effects of Subthalamic and Nigral Stimulation on Gait Kinematics in Parkinson's disease. Frontiers in neurology, 8, 543.
Seidel, K., Bouzrou, M., Heidemann, N., Krüger, R., Schols, L., den Dunnen, W. F. A., Korf, H.-W., & Rub, U. (2017). Involvement of the cerebellum in Parkinson disease and dementia with Lewy bodies. Annals of neurology, 81(6), pp. 898-903.
Straniero, L., Rimoldi, V., Samarani, M. et al. (2017). The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p. Sci Rep, 7, 12702. https://doi.org/10.1038/s41598-017-12973-5
Trezzi, J., Galozzi, S., Jaeger, C., Barkovits, K., Brockmann, K., Maetzler, W., Berg, D., Marcus, K., Betsou, F., Hiller, K., Mollenhauer, B. (2017) Distinct Metabolomic Signature in Cerebrospinal Fluid in Early Parkinson’s Disease, Movement Disorders,10, pp. 1401, doi: 10.1002/mds.27132
Wang, L., Heckman, M. G., Aasly, J. O., Annesi, G., Bozi, M., Chung, S. J., Clarke, C., Crosiers, D., Eckstein, G., Garraux, G., Hadjigeorgiou, G. M., Hattori, N., Jeon, B., Kim, Y. J., Kubo, M., Lesage, S., Lin, J. J., Lynch, T., Lichtner, P., Mellick, G. D., Mok, V., Morrison, K. E., Quattrone, A., Satake, W., Silburn, P. A., Stefanis, L., Stockton, J. D., Tan, E. K., Toda, T., Brice, A., Van Broeckhoven, C., Uitti, R. J., Wirdefeldt, K., Wszolek, Z., Xiromerisiou, G., Maraganore, D. M., Gasser, T., Krüger, R., Farrer, M. J., Ross, O. A., & Sharma, M. (2017). Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study. Neurobiology of aging, 49, 217.e1-217.e4.
2016
Guebila, M. B., & Thiele, I. (2016). Model-based dietary optimization for late-stage, levodopa-treated, Parkinson’s disease patients. Npj Systems Biology and Applications, 2(1). doi:10.1038/npjsba.2016.13 >> Read the summary
Heinzel, S., Roeben, B., Ben-Shlomo, Y., Lerche, S., Alves, G., Barone, P., Behnke, S., Berendse, H. W., Bloem, B. R., Burn, D., Dodel, R., Grosset, D. G., Hu, M., Kasten, M., Krüger, R., Moccia, M., Mollenhauer, B., Oertel, W., Suenkel, U., Walter, U., … Berg, D. (2016). Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned. Frontiers in aging neuroscience, 8, 147. https://doi.org/10.3389/fnagi.2016.00147
Krüger, R., Hilker, R., Winkler, C., Lorrain, M., Hahne, M., Redecker, C., Lingor, P., & Jost, W. H. (2016). Advanced stages of PD: interventional therapies and related patient-centered care. Journal of neural transmission (Vienna, Austria : 1996), 123(1), 31–43. https://doi.org/10.1007/s00702-015-1418-0 >> Read the summary
Weiss, D., Herrmann, S., Wang, L., Schulte, C., Brockmann, K., Plewnia, C., Gasser, T., Sharma, M., Gharabaghi, A., Krüger, R. (2016). Alpha-synuclein gene variants may predict neurostimulation outcome. Movement Disorders, 31(4), 601-603. doi:10.1002/mds.26558
Wüst, R., Maurer, B., Hauser, K., Woitalla, D., Sharma, M., & Krüger, R. (2016). Mutation analyses and association studies to assess the role of the presenilin-associated rhomboid-like gene in Parkinson's disease. Neurobiology of aging, 39, . https://doi.org/10.1016/j.neurobiolaging.2015.11.025
2015
Hipp, G. (2015). Das Luxemburger Parkinson-Kohortenprogramm: Neue Strategien für eine umfassende Studie zur Erfassung von Biodaten und klinischen Daten. Basal Ganglia, 5(1). doi:10.1016/j.baga.2015.02.246